NCT06781034 Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies
| NCT ID | NCT06781034 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nīmes |
| Condition | Cerebral Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 128 participants |
| Start Date | 2025-02-03 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 128 participants in total. It began in 2025-02-03 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced MRI. By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.
Eligibility Criteria
Inclusion Criteria: * Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital; * Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up. Exclusion Criteria: * Patient refusing to participate
Contact & Investigator
Anissa MEGZARI
STUDY DIRECTOR
Centre Hospitalier Universitaire de Nīmes
Frequently Asked Questions
Who can join the NCT06781034 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cerebral Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06781034 currently recruiting?
Yes, NCT06781034 is actively recruiting participants. Contact the research team at teodora.parvu@chu-nimes.fr for enrollment information.
Where is the NCT06781034 trial being conducted?
This trial is being conducted at Nîmes, France.
Who is sponsoring the NCT06781034 clinical trial?
NCT06781034 is sponsored by Centre Hospitalier Universitaire de Nīmes. The principal investigator is Anissa MEGZARI at Centre Hospitalier Universitaire de Nīmes. The trial plans to enroll 128 participants.